Radius Health (RDUS) Shares are Down -4.3%

Radius Health (RDUS) : During the past 4 weeks, traders have been relatively bearish on Radius Health (RDUS), hence the stock is down -3.85% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.46% relative to the S&P 500. The 4-week change in the price of the stock is -4.37% and the stock has fallen -4.3% in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.03% and the 50-Day Moving Average is 1.07%.The 200 Day SMA reached 30.47%


Radius Health (NASDAQ:RDUS): The stock opened in the green at $55.4 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $55.68 and a low of $53.13 for the day. The stock did not find buyers even at the lows and closed at $54.09 recording a loss of -2.01%. 1,164,909 shares exchanged hands during the trading day. The stock had closed at $54.09 in the previous days trading.

Radius Health (RDUS) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $78 and the lowest price target forecast is $24. The average forecast of all the analysts is $57.8 and the expected standard deviation is $22.43.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.